Discover 870 paid clinical trials in Tuscaloosa, Alabama. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 870
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
for
Pancreatic Cancer
Location: Birmingham AL, St Louis MO, Cleveland OH, Duarte CA
Sponsor: Varian, a Siemens Healthineers Company
Sex: All
Age: 18+
Code: NCT05764720
Recruiting
Kidney Function in People With Cystic Fibrosis in the Era of HEMT
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
for
Neoplasm Metastasis, Non-Small Cell Lung Cancer
Location: Birmingham AL, Atlanta GA, Nashville TN, Houston TX,
Sponsor: Boehringer Ingelheim
Sex: All
Age: 18+
Code: NCT04886804
Phase 1, Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
for
Pulmonary Disease, Chronic Obstructive
Location: Birmingham AL, Indianapolis IN, Orlando FL, Muncie IN,
Sponsor: Eli Lilly and Company
Sex: All
Age: 40 - 70+
Code: NCT07759245
Phase 2, Recruiting
Leading Healthy Eating and Activity Promotion Program
for
Cancer Survivor, Cancer, Oncology
Location: Birmingham AL
Sponsor: University of Alabama at Birmingham
Sex: All
Age: 18 - 70+
Code: NCT06868524
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
for
Alopecia Areata
Location: Birmingham AL, Indianapolis IN, Webster TX, Tulsa OK,
Sponsor: Pfizer
Sex: All
Age: 12+
Code: NCT06873945
Phase 3, Recruiting
Process-Based Approach Case Series For Anxiety Problems
for
Anxiety
Location: Birmingham AL
Sponsor: University of Alabama at Birmingham
Sex: All
Age: 18+
Code: NCT07352592
Recruiting
Boosting Olfactory and Sensory Training Study (BOOST)
for
HIV (Human Immunodeficiency Virus)
Location: Birmingham AL
Sponsor: University of Alabama at Birmingham
Sex: All
Age: 40+
Code: NCT07221123
Phase 2, Recruiting
Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma
for
Posterior Fossa Ependymal Tumor
Location: Birmingham AL, St Louis MO, Durham NC,
Sponsor: University of California, San Francisco
Sex: All
Age: 1 - 39
Code: NCT07226453
Phase 2, Recruiting
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
for
Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer,
Location: Birmingham AL, Nashville TN, Knoxville TN, St Louis MO,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT07154290
Phase 2, Recruiting
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
for
Major Depressive Disorder (MDD)
Location: Birmingham AL, Flowood MS, Atlanta GA, Decatur GA,
Sponsor: Supernus Pharmaceuticals, Inc.
Sex: All
Age: 18 - 70
Code: NCT07226661
Phase 2, Recruiting
VENTURI (VENTilation Using Respiratory Imaging)
for
Asthma
Location: Birmingham AL
Sponsor: University of Alabama at Birmingham
Sex: All
Age: 18 - 70+
Code: NCT07282886
Phase 2, Recruiting
To Compare Post-Extraction Use of a Novel Ethylenediaminetetraacetic Acid (EDTA) Post-operative Mouth Rinse and Daily Use EDTA Mouth Rinse and Standard 0.12% Chlorhexidine (CHX) Post-operative Mouth Rinse and Daily Use Essential Oil (EO) Mouth Rinse.
for
Extraction Sites After Removal and Bone Replacement Grafting at Extraction Sockets of Dentally Hopeless Single-rooted Teeth,
Location: Birmingham AL
Sponsor: University of Alabama at Birmingham
Sex: All
Age: 18 - 70+
Code: NCT07191262
Recruiting
Black and African Americans Connections to Parkinson's Disease (BLAAC PD)
for
Parkinson Disease
Location: Birmingham AL, New Orleans LA, Shreveport LA,
Sponsor: Michael J. Fox Foundation for Parkinson's Research
Sex: All
Age: 18+
Code: NCT06719583
Recruiting
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC